



(19) REPUBLIKA HRVATSKA
DRŽAVNI ZAVOD ZA
INTELEKTUALNO VLASNIŠTVO



(10) Identifikator
dokumenta:

HR P20220899 T1

HR P20220899 T1

(12) **PRIJEVOD PATENTNIH ZAHTJEVA
EUROPSKOG PATENTA**

(51) MKP:

A61P 31/12 (2006.01) **A61P 31/18** (2006.01)
A61P 43/00 (2006.01) **C07D 471/22** (2006.01)
A61K 31/4985 (2006.01) **C07D 498/18** (2006.01)
C07D 487/14 (2006.01) **C07D 471/18** (2006.01)
A61K 45/06 (2006.01) **A61K 31/553** (2006.01)
A61K 31/529 (2006.01)

(46) Datum objave prijevoda patentnih zahtjeva: 28.10.2022.

(21) Broj predmeta: P20220899T

(22) Datum podnošenja: 19.12.2013.

(96) Broj europske prijave patenta: EP 19185121.1
Datum podnošenja europske prijave patenta: 19.12.2013.

(97) Broj objave europske prijave patenta: EP 3608325 A1
Datum objave europske prijave patenta: 12.02.2020.

(97) Broj objave europskog patenta: EP 3608325 B1
Datum objave europskog patenta: 06.07.2022.

(31) Broj prve prijave: 201261745375 P (32) Datum podnošenja prve prijave: 21.12.2012. (33) Država ili organizacija podnošenja prve prijave: US
201361788397 P 15.03.2013. US
201361845803 P 12.07.2013. US

(62) Broj i datum prvobitne prijave u slučaju podjele patenta: 13815937.1 19.12.2013.

(62) Broj i datum prvobitne prijave u slučaju podjele patenta: 15201519.4 19.12.2013.

(73) Nositelj patenta: **Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, US**

(72) Izumitelji: **Jin Haolun, c/o Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, US**
Scott E. Lazerwith, c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, US
Teresa Alejandra Trejo Martin, c/o Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, US
Elizabeth M. Bacon, c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, US
Jeromy J. Cottell, c/o Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, US
Zhenhong R. Cai, c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, US
Hyung-jung Pyun, c/o Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, US
Phillip Anthony Morganelli, c/o Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, US
Mingzhe Ji, c/o Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, US
James G. Taylor, c/o Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, US
Xiaowu Chen, c/o Gilead Sciences Inc. 333 Lakeside Drive, Foster City, CA 94404, US
Michael R. Mish, c/o Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, US
Manoj C. Desai, c/o Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, US


(74) Zastupnik: Vukmir i suradnici odvjetničko društvo d.o.o., 10000 Zagreb, HR

(54) Naziv izuma: **SPOJEVI POLICIKLIČKOG KARBAMOILPIRIDONA I NJIHOVA FARMACEUTSKA UPORABA**

HR P20220899 T1

PATENTNI ZAHTEJEVI

1. Spoj, **naznačen time, da** je predstavljen Formulom (I):



(I)

ili stereoisomer ili njegova farmaceutski prihvatljiva sol,
u kojoj:

X je -O-;

W je -CHZ²-;

Z¹ i Z² kada se uzmu zajedno, tvore -L- gdje L je -C(R^a)₂C(R^a)₂-;


Z⁴ je -CH₂-;

svaki Y¹ i Y² je neovisno vodik, C₁₋₃ alkil, ili C₁₋₃ haloalkil;

R¹ je fenil supstituiran s jednim ili dva halogena; i





svaki R^a je neovisno vodik, halogen, hidroksi ili C₁₋₄ alkil.












2. Spoj prema patentnom zahtjevu 1, **naznačen time, da** je predstavljen Formulom (II-A):



(II-A)











3. Spoj prema patentnom zahtjevu 1, **naznačen time, da** svaki Y¹ i Y² je neovisno vodik, metil, ili trifluorometil.
4. Spoj prema patentnom zahtjevu 1 ili zahtjevu 2, **naznačen time, da** R¹ je supstituiran s jednim halogenom.
5. Spoj prema patentnom zahtjevu 4, **naznačen time, da** R¹ je 4-fluorofenil ili 2-fluorofenil.
6. Spoj prema patentnom zahtjevu 1 ili zahtjevu 2, **naznačen time, da** R¹ je supstituiran s dva halogena.
7. Spoj prema patentnom zahtjevu 6, **naznačen time, da** R¹ je 2,4-difluorofenil, 2,3-difluorofenil, 2,6-difluorofenil, 3-fluoro-4-klorofenil, 3,4-difluorofenil, 2-fluoro-4-klorofenil, ili 3,5-difluorofenil.
8. Spoj prema patentnom zahtjevu 7, **naznačen time, da** R¹ jest 2,4-difluorofenil.
9. Spoj prema patentnom zahtjevu 1, **naznačen time, da** se bira od sljedećih:





5

10



5

10

i

10. Farmaceutski pripravak, **naznačen time, da** sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili stereoisomer ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćno sredstvo.
- 5 11. Farmaceutski pripravak prema patentnom zahtjevu 10, **naznačen time, da** nadalje sadrži jedno ili više dodatnih terapijskih sredstava.
12. Farmaceutski pripravak prema patentnom zahtjevu 11, **naznačen time, da** jedno ili više dodatnih terapijskih sredstava jest sredstvo protiv virusa humane imunodeficijencije.
- 10 13. Farmaceutski pripravak prema patentnom zahtjevu 12, **naznačen time, da** se jedno ili više dodatnih terapijskih sredstava bira iz skupine koju čine inhibitori proteaze virusa humane imunodeficijencije, nenukleozidni inhibitori reverzne transkriptaze virusa humane imunodeficijencije, nukleozidni inhibitori reverzne transkriptaze virusa humane imunodeficijencije, nukleotidni inhibitori reverzne transkriptaze virusa humane imunodeficijencije, i njihove kombinacije.